Limits...
In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.

Park JC, Lee YJ, Choi HY, Shin YK, Kim JD, Ku SK - Evid Based Complement Alternat Med (2014)

Bottom Line: The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals).Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses.Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Internal Medicine of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, No. 1 Haanydae-ro, Gyeongsan, Gyeongbuk 712-715, Republic of Korea.

ABSTRACT
Platycodin D is a major pharmacological constituent of Platycodi radix and has showed various pharmacological activities through oxidative stress defense mechanisms. Here, possible antitumor, anticachexia, and immunomodulatory activities of platycodin D were observed on the H520 tumor cell-bearing athymic nude mice after confirming the in vitro cytotoxicity. Platycodin D was orally administered at dose levels of 200, 100, and 50 mg/kg, once a day for 35 days from 15 days after implantation. The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals). Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses. Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects. Gemcitabine showed favorable cytotoxity against H520 tumor cell and related in vivo antitumor effects but aggravated the cancer related cachexia and immunosuppress in H520 tumor cell-bearing athymic nude mice. Taken together, it is considered that oral treatment of platycodin D has potent antitumor activities on H520 cells through direct cytotoxic effects, increases of apoptosis in tumor cells, and immunostimulatory effects and can be control cancer related cachexia.

No MeSH data available.


Related in: MedlinePlus

Changes on the serum IL-6 and IFN-γ levels in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (pg/ml); TB = tumor-bearing; IL = interleukin; IFN = interferon Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; Platycodin D was orally administered, once a day; aP < 0.01 and bP < 0.05 as compared with intact control by MW test; cP < 0.01 and dP < 0.05 as compared with TB control by MW test.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4247928&req=5

fig6: Changes on the serum IL-6 and IFN-γ levels in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (pg/ml); TB = tumor-bearing; IL = interleukin; IFN = interferon Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; Platycodin D was orally administered, once a day; aP < 0.01 and bP < 0.05 as compared with intact control by MW test; cP < 0.01 and dP < 0.05 as compared with TB control by MW test.

Mentions: Significant (P < 0.01) increases of the serum IL-6 levels, and decreases of IFN-γ levels were observed in tumor-bearing control mice as compared with intact control mice, respectively. However, platycodin D 200, 100 and 50 mg/kg administered mice showed significant (P < 0.01 or P < 0.05) decreases of serum IL-6 levels, and increases of IFN-γ levels as compared with tumor-bearing control, dose-dependently. Gemcitabine 160 mg/kg treated mice showed significant (P < 0.05) aggravated the serum IL-6 and IFN-γ level changes, induced by H520 tumor-bearing in this study (Figure 6).


In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.

Park JC, Lee YJ, Choi HY, Shin YK, Kim JD, Ku SK - Evid Based Complement Alternat Med (2014)

Changes on the serum IL-6 and IFN-γ levels in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (pg/ml); TB = tumor-bearing; IL = interleukin; IFN = interferon Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; Platycodin D was orally administered, once a day; aP < 0.01 and bP < 0.05 as compared with intact control by MW test; cP < 0.01 and dP < 0.05 as compared with TB control by MW test.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4247928&req=5

fig6: Changes on the serum IL-6 and IFN-γ levels in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (pg/ml); TB = tumor-bearing; IL = interleukin; IFN = interferon Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; Platycodin D was orally administered, once a day; aP < 0.01 and bP < 0.05 as compared with intact control by MW test; cP < 0.01 and dP < 0.05 as compared with TB control by MW test.
Mentions: Significant (P < 0.01) increases of the serum IL-6 levels, and decreases of IFN-γ levels were observed in tumor-bearing control mice as compared with intact control mice, respectively. However, platycodin D 200, 100 and 50 mg/kg administered mice showed significant (P < 0.01 or P < 0.05) decreases of serum IL-6 levels, and increases of IFN-γ levels as compared with tumor-bearing control, dose-dependently. Gemcitabine 160 mg/kg treated mice showed significant (P < 0.05) aggravated the serum IL-6 and IFN-γ level changes, induced by H520 tumor-bearing in this study (Figure 6).

Bottom Line: The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals).Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses.Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Internal Medicine of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, No. 1 Haanydae-ro, Gyeongsan, Gyeongbuk 712-715, Republic of Korea.

ABSTRACT
Platycodin D is a major pharmacological constituent of Platycodi radix and has showed various pharmacological activities through oxidative stress defense mechanisms. Here, possible antitumor, anticachexia, and immunomodulatory activities of platycodin D were observed on the H520 tumor cell-bearing athymic nude mice after confirming the in vitro cytotoxicity. Platycodin D was orally administered at dose levels of 200, 100, and 50 mg/kg, once a day for 35 days from 15 days after implantation. The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals). Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses. Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects. Gemcitabine showed favorable cytotoxity against H520 tumor cell and related in vivo antitumor effects but aggravated the cancer related cachexia and immunosuppress in H520 tumor cell-bearing athymic nude mice. Taken together, it is considered that oral treatment of platycodin D has potent antitumor activities on H520 cells through direct cytotoxic effects, increases of apoptosis in tumor cells, and immunostimulatory effects and can be control cancer related cachexia.

No MeSH data available.


Related in: MedlinePlus